Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Laboratory of Pediatric Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Gastrointest Surg. 2024 Aug;28(8):1234-1241. doi: 10.1016/j.gassur.2024.05.011. Epub 2024 May 11.
This study aimed to assess the efficacy of surgery as a treatment option for patients with signet-ring cell carcinoma (SRCC) in the gastrointestinal tract (GI-SRCC).
Using the Surveillance, Epidemiology, and End Results database, patients with GI-SRCC who underwent surgery or received nonsurgical treatment were included. Propensity score matching (PSM) analysis was used to balance baseline characteristics and reduce bias. Overall survival (OS) was calculated in matching cohorts to estimate prognosis for patients with GI-SRCC. Nomogram was established to predict metastasis for patients with GI-SRCC.
The study enrolled a total of 9428 patients with GI-SRCC, with 1689 patients in the nonsurgery group and 7739 patients in the surgery group. After 1:1 PSM, we analyzed 743 patients from each group. Our survival analyses revealed that surgery independently correlated with improved OS for patients with GI-SRCC (hazard ratio, 0.37; 95% CI, 0.33-0.42; P < .001). Subgroup analysis further confirmed the positive impact of surgery on the prognosis of patients with nonmetastatic GI-SRCC. Notably, distinct subsets of patients with metastasis, particularly those originating from the upper GI (esophagus, proximal stomach, and distal stomach) and left colon, demonstrated a significant improvement in OS after surgery. However, no significant survival difference was observed for patients with metastatic right colon and rectum SRCC. Using nomogram, we quantitatively assessed the risk of metastasis in patients with right colon and rectum SRCC, which exhibited robust predictive accuracy, with area under the curve values of 0.829.
Our study highlighted surgery's positive impact on prognosis for both patients with nonmetastatic and metastatic upper GI-SRCC and left colon SRCC. Hence, we recommend surgery as a treatment option for these groups. In addition, for patients with metastatic right colon and rectum SRCC ineligible for surgery, our predictive nomogram can offer a convenient tool to aid early intervention and improve prognosis.
本研究旨在评估手术作为治疗胃肠道(GI-SRCC)中印戒细胞癌(SRCC)患者的治疗选择的疗效。
使用监测、流行病学和最终结果数据库,纳入接受手术或非手术治疗的 GI-SRCC 患者。采用倾向评分匹配(PSM)分析来平衡基线特征并减少偏差。在匹配队列中计算总生存期(OS)以估计 GI-SRCC 患者的预后。建立列线图以预测 GI-SRCC 患者的转移情况。
本研究共纳入 9428 例 GI-SRCC 患者,其中非手术组 1689 例,手术组 7739 例。经过 1:1 PSM 后,我们对每组中的 743 例患者进行了分析。我们的生存分析表明,手术与 GI-SRCC 患者的 OS 改善独立相关(风险比,0.37;95%CI,0.33-0.42;P<.001)。亚组分析进一步证实了手术对非转移性 GI-SRCC 患者预后的积极影响。值得注意的是,转移患者的不同亚组,特别是来自上胃肠道(食管、近端胃和远端胃)和左结肠的患者,手术后 OS 显著改善。然而,转移性右结肠和直肠 SRCC 患者的生存无显著差异。使用列线图,我们定量评估了右结肠和直肠 SRCC 患者转移的风险,该模型具有强大的预测准确性,曲线下面积值为 0.829。
我们的研究强调了手术对非转移性和转移性上胃肠道-SRCC 和左结肠 SRCC 患者预后的积极影响。因此,我们建议将手术作为这些患者的治疗选择。此外,对于不符合手术条件的转移性右结肠和直肠 SRCC 患者,我们的预测列线图可以提供一种方便的工具,以帮助早期干预和改善预后。